Understanding the role of the duration of untreated illness in psychiatric disorders: A narrative review;Una revisione critica sul ruolo della durata di malattia non trattata nei disturbi psichiatrici

Rivista di Psichiatria

Volumn 45, Issue 4, 2010, Pages 197-208

  Altamura, Alfredo Carlo ^a   Camuri, Giulia ^a   Dell'Osso, Bernardo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anxiety disorders; Duration of untreated illness (dui); Duration of untreated psychosis (dup); Mood disorders; Schizophrenia

Indexed keywords

ANXIETY DISORDER; DISEASE COURSE; DISEASE DURATION; HEALTH PROGRAM; HUMAN; MOOD DISORDER; PROGNOSIS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ANXIETY DISORDERS; DEPRESSIVE DISORDER; DISEASE PROGRESSION; HUMANS; MOOD DISORDERS; PROGNOSIS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77958048569     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Malla A, Norman R, McLean T, Scholten D, Townsend L. A Canadian programme for early intervention in non-affective psychotic disorders. Aust New Zeal J Psychiatr 2003; 37: 407-13.
2. Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, et al.Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry 2004; 61: 143-50.
3. Melle I, Larsen TK, Haahr U, Friis S, Johannesen JO, Opjordsmoen S, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry 2008; 65: 634-40.
4. Jackson D, Lawoyin R, Gaynor K, Clarke M, Browne S, Renwick L, et al. Is the duration of untreated psychosis temporally stable? Eur Psychiatry 2008; 23: 97-9.
5. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review.Arch Gen Psychiatry 2005; 62: 975-83.
6. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in firstepisode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-804.
7. Clarke M, Whitty P, Browne S, Mc Tigue O, Kinsella A, Waddington JL, et al. Suicidality in first episode psychosis. Schiz Res 2006; 86: 221-5.
8. Franz L, Carter T, Leiner AS, Bergner E, Thompson NJ, Compton MT. Stigma and treatment delay in first-episode psychosis: a grounded theory study. Early Interv Psychiatry. 2010; 4: 47-56.
9. Freidl M, Piralic Spitzl S, Aigner M. How depressive symptoms correlate with stigma perception of mental illness. Int Rev Psychiatry 2008; 20: 510-4.
10. Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008; 42: 982-90.
11. Jeppesen P, Petersen L, Thorup A, Abel MB, Øhlenschlaeger J, Christensen TØ, et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med 2008; 38: 1157-66.
12. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry 2002; 63: 985-91.
13. Mantere O, Suominen K, Leppämäki S, Valtonen H, Arvilommi P, Isometsä E. The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi Bipolar Study (JoBS). Bipolar Disord 2004; 6: 395-405.
14. Bauer M, Juckel G, Correll CU, Leopold K, Pfennig A. Diagnosis and treatment in the early illness phase of bipolar disorders. Eur Arch Psychiatr Clin Neurosci 2008; 258: 50-4.
15. Altamura AC, Buoli M, Albano A, Dell'Osso B. Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study. Int Clin Psychopharmacol 2010; 25: 172-9.
16. Singh SP. Outcome measures in early psychosis; relevance of duration of untreated psychosis. Br J Psychiatry (suppl) 2007; 50: 58-63.
17. Bechard-Evans L, Schmitz N, Abadi S, Joober R, King S, Malla A. Determinants of help-seeking and system related components of delay in the treatment of first-episode psychosis. Schizophr Res 2007; 96: 206-14.
18. Barnes TR, Hutton SB, Chapman MJ, Mutsatsa S, Puri BK, Joyce EM. West London first-episode study of schizophrenia. Clinical correlates of duration of untreated psychosis. Br J Psychiatry 2000; 177: 207-11.
19. Jané-Llopis E, Hosman C, Jenkins R, Anderson P. Predictors of efficacy in depression prevention programmes. Meta-analysis. Br J Psychiatry 2003; 183: 384-97.
20. Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am J Psychiatry 2008; 165: 1015-23.
21. Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley RW. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry 2007; 64: 521-9.
22. Lawrie SM, McIntosh AM, Hall J, Owens DG, Johnstone EC. Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull 2008; 34: 330-40.
23. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008; 34: 354-66.
24. Cahn W, Rais M, Stigter FP, van Haren NE, Caspers E, Hulshoff Pol HE, et al. Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol 2009; 19: 147-51.
25. Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 2005; 79: 85-93.
26. Goldberg TE, Burdick KE, McCormack J, Napolitano B, Patel RC, Sevy SM, et al. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophr Res 2009; 107: 262-6.
27. Lappin JM, Morgan KD, Morgan C, Dazzan P, Reichenberg A, Zanelli JW, et al. Duration of untreated psychosis and neuropsychological function in first episode psychosis. Schizophr Res 2007; 95: 103-10.
28. Simonsen E, Friis S, Haahr U, Johannessen JO, Larsen TK, Melle I, et al. Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatr Scand 2007; 116: 54-61.
29. Barnes TR, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry 2008; 193: 203-9.
30. Altamura AC, Bassetti R, Sassella F, Salvadori D, Mundo E. Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res 2001; 52: 29-36.
31. Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 2003; 60: 47-55.
32. Barrett EA, Sundet K, FaerdenA,Nesvåg R,Agartz I, Fosse R, et al. Suicidality before and in the early phases of first episode psychosis. Schizophr Res 2010; 119: 11-17.
33. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996; 3: 241-53.
34. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia.Arch Gen Psychiatry 1995; 52: 998-1007.
35. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007; 22: 249-67.
36. Bangalore SS, Goradia DD, Nutche J, Diwadkar VA, Prasad KM, Keshavan MS. Untreated illness duration correlates with gray matter loss in first-episode psychoses. Neuroreport 2009; 20: 729-34.
37. Velakoulis D, Wood SJ, Soulsby B, Brewer W, Leeton L, Desmond P, et al. Increased duration of illness is associated with reduced volume in right medial temporal/anterior cingulate grey matter in patients with chronic schizophrenia. Schizophr Res 2002; 57: 43-9.
38. Hoff AL, Sakuma M, Razi K, Heydebrand G, Csemansky JG, DeLisi LE. Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia. Am J Psychiatry 2000; 157: 1824-8.
39. Ho BC, Alicata D, Ward J, Moser DJ, O'Leary DS,Amdt S, et al.Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia.Am J Psychiatry 2003; 160: 142-8.
40. Häfner H, Löffler W, Maurer K, Hambrecht M, Van der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 1999; 100: 105-18.
41. Morgan C, Abdul-Al R, Lappin JM, Jones P, Fearon P, Leese M, et al. Clinical and social determinants of duration of untreated psychosis in the AESOP first-episode psychosis study. Br J Psychiatry 2006; 189: 446-52.
42. Norman RM, Malla AK, Manchanda R. Delay in treatment for psychosis; its relation to family history. Soc Psych Psychiatr Epidemiol 2007; 42: 507-12.
43. de Haan L, Peters B, Dingemans P,Wouters L, Linszen D. Attitudes of patients toward the first psychotic episode and the start of treatment. Schizofr Bull 2002; 28: 431-42.
44. Keshavan MS, Haas G, Miewald J, Montrose DM, Reddy R, Schooler NR. Prolonged untreated illness duration from prodromal onset predicts outcome in first episode of psychoses. Schizophr Bull 2003; 29: 757-69.
45. O'Callaghan E, Turner N, Renwick L, Jackson D, Sutton M, Foley SD, et al. First episode psychosis and the trail to secondary care: help-seeking and health-system delays. Soc Psych Psychiatr Epidemiol 2010; 45: 381-9.
46. Wyatt RL. Neuroleptics and the natural course of schizofrenia. Schizophr Bull 1991; 17: 325-51.
47. Owens DC, Johnstone EC, Miller P, Macmillan JF, Crow TJ. Duration of untreated illness and outcome in schizophrenia: test of predictions in relation to relapse risk. Br J Psychiatr 2010; 196: 296-301.
48. Verdoux H, Liraud F, Bergey C,Assens F,Abalan F, van Os J. Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophr Res 2001; 49: 231-41.
49. Norman RM, Malla AK, Manchanda R. Early premorbid adjustment as a moderator of the impact of duration of untreated psychosis. Schizophr Res 2007; 95: 111-4.
50. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 2009; 30: 3719-35.
51. Altamura AC, Dell'Osso B, Vismara S, Mundo E. May duration of untreated illness influence the long-term course of major depressive disorder? Eur Psychiatry 2008; 23: 92-6.
52. Scott J, Eccleston D, Boys R. Can we predict the persistence of depression? Br J Psychiatry 1992; 161: 633-7.
53. Gormley N,O'Leary D,Costello F. First admissions for depression: is the 'no-treatment interval' a critical predictor of time to remission? J Affect Disord 1999; 54: 49-54.
54. Altamura AC, Dell'Osso B, Mundo E, Dell'Osso L. Duration of untreated illness in major depressive disorder: a naturalistic study. Int J Clin Practice 2007; 61: 697-700.
55. de Diego-Adeliño J, Portella MJ, Puigdemont D, Pérez-Egea R, Alvarez E, Pérez V. A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. J Affect Disord 2010; 120: 221-5.
56. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I:Treatment of bipolar depression.World J Biol Psychiatry 2002; 3: 115-24.
57. Suppes T, Dennehy EB, Hirschfeld RM,Altshuler LL, Bowden CL, Calabrese JR, et al. Texas consensus conference panel on medication treatment of bipolar disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66: 870-86.
58. Arvilommi P, Suominen KS,Mantere OK, Leppämäki S, Valtonen H, Isometsä ET. Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders. J Clin Psychiatry 2007; 68: 102-10.
59. Suominen K,Mantere O,Valtonen H,Arvilommi P, Leppämäki S, Paunio T, et al.Early age at onset of bipolar disorder is associated with more severe clinical features but delayed treatment seeking. Bip Disord 2007; 9: 698-705.
60. Altamura AC, Dell'Osso B, Berlin HA, Buoli M, Bassetti R. Duration of untreated illness and suicide in bipolar disorder: a naturalistic study.EurArch Psychiatry Clin Neurosci 2009 Nov 13 [Epub ahead of print].
61. Baethge C, Gruschka P, Smolka MN, Berghöfer A, Bschor T, Müller-Oerlinghausen B, et al. Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder. J Psych Neurosci 2003; 28: 355-61.
62. Baethge C, Tondo L, Bratti IM, Bschor T, Bauer M, Viguera AC, et al. Prophylaxis latency and outcome in bipolar disorders. Can J Psychiatry 2003; 48: 449-57.
63. Norrholm SD, Ouimet CC. Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. Synapse 2001; 42: 151-63.
64. Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: perspective from affective neuroscience. Ann Rev Psychol 2002; 53: 545-74.
65. Bremner JD, Narayan M,Anderson ER, Staib LH,Miller HL, Charney DS.Hippocampal volume reduction in major depression. Am J Psychiatry 2000; 157: 115-8.
66. Videbech P, Ravnkilde B. Hippocampal volume and depression. A meta-analysis of MRI studies. Am J Psychiatry 2004; 161: 1957-66.
67. Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S, et al.Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 2002; 51: 273-9.
68. Hamidi M, DrevetsWC, Price JL. Glial reduction in amygdale is due to oligodendrocytes. Biol Psychiatry 2004; 55: 563-9.
69. Cotter D,Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58: 545-53.
70. DrevetsWC, Price JL, Simpson JR Jr,Todd RD, Reich T,Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386: 824-7.
71. Ongür D,DrevetsWC, Price JL.Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci 1998; 95: 13290-5.
72. Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000; 5: 262-9.
73. Manji HK,Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001; 35: 5-49.
74. Duman RS,Malberg J,Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999; 46: 1181-91.
75. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacol 2001; 25: 836-44.
76. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
77. Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacol 2003; 28: 1562-71.
78. Lucassen PJ, Fuchs E, Czéh B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry 2004; 55: 789-96.
79. Yucel K, McKinnon MC, Chahal R, Taylor VH, Macdonald K, Joffe R, et al. Anterior cingulated volumes in never-treated patients with major depressive disorder. Neuropsychopharmacol 2008; 33: 3157-63.
80. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 19: 5034-43.
81. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss.Am J Psychiatry 2003; 160: 1516-8.
82. Bienvenu OJ, Ginsburg GS. Prevention of anxiety disorders. Int Rev Psychiatry 2007; 19: 647-54.
83. Roberts NP, Kitchiner NJ, Kenardy J, Bisson JI. Systematic review and meta-analysis of multiple-session early interventions following traumatic events.Am J Psychiatry 2009; 166: 293-301.
84. Yung AR, Killackey E, Hetrick SE, Parker AG, Schultze-Lutter F, Klosterkoetter J, et al. The prevention of schizophrenia. Int Rev Psychiatry 2007; 19: 633-34.
85. Wagner R, Silove D, Marnane C, Rouen D. Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. J Anx Disord 2006; 20: 363-71.
86. Altamura AC, Santini A, Salvadori D, Mundo E. Duration of untreated illness in panic disorder: a poor outcome risk factor? J Neuropsychiatr Dis Treat 2005; 1: 345-71.
87. Altamura AC, Dell'Osso B, D'Urso N, Russo M, Fumagalli S, Mundo E.Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectrums 2008; 13: 415-22.
88. Dell'Osso B, Buoli M, Hollander, Colombini G, Mundo E, Altamura AC. Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World J Biol Psychiatr 2010; 11: 59-65.
89. Marshall M, Rathbone J. Early intervention in psychosis. Cochrane Database Syst Rev 2006; 18: CD004718.
90. Schultze-Lutter F, Ruhrmann S, Klosterkötter J. Early detection of psychosis - establishing a service for persons at risk. Eur Psychiatry 2009; 24: 1-10.
91. Francey SM, Nelson B, Thompson A, Parker AG, Kerr M, Macneil C, et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res 2010; 119: 1-10.
92. Joa I, Johannessen JO, Auestad B, Friis S, McGlashan T, Melle I, et al. The key to reducing duration of untreated first psychosis: information campaigns. Schizophr Bull 2008; 34: 466-72.
93. McWilliams S, Egan P, Jackson D, Renwick L, Foley S, Behan C, et al. Caregiver psychoeducation for first-episode psychosis. Eur Psychiatry 2010; 25: 33-8.
94. Merry S, McDowell H, Hetrick S, Bir J, Muller N. Psychological and/or educational interventions for the prevention of depression in children and adolescents. Cochrane Database Syst Rev 2004; 1: CD003380.
95. Cuijpers P, Van Straten A, Smit F. Preventing the incidence of new cases of mental disorders: a meta-analytic review. J Nerv Ment Dis 2005; 193: 119-25.
96. Horowitz JL, Garber J. The prevention of depressive symptoms in children and adolescents: a meta-analytic review. J Consult Clin Psychol 2006; 74: 401-15.
97. Sutton JM. Prevention of depression in youth: a qualitative review and future suggestions. Clin Psychol Rev 2007; 27: 552-71.
98. Cuijpers P, van Straten A, Smit F, Mihalopoulos C, Beekman A. Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. Am J Psychiatry 2008; 165: 1272-80.
99. Gladstone TR,BeardsleeWR.The prevention of depression in children and adolescents: a review. Can J Psychiatry 2009; 54: 212-21.
100. Stice E, Shaw H, Bohon C,Marti CN, Rohde P.A meta-analytic review of depression prevention programs for children and adolescents: factors that predict magnitude of intervention effects. J Consult Clin Psychol 2009; 77: 486-503.
101. Larun L, Nordheim LV, Ekeland E, Hagen KB, Heian F. Exercise in prevention and treatment of anxiety and depression among children and young people. Cochrane Database Syst Rev 2006; 3: CD004691.
102. Pratt BM, Woolfenden SR. Interventions for preventing eating disorders in children and adolescents. Cochrane Database of Syst Rev 2002; 2: CD002891.
103. Griffin KW, Botvin GJ, Nichols TR, Doyle MM. Effectiveness of a universal drug abuse prevention approach for youth at high risk for substance use initiation. Prev Med 2003; 36: 1-7.